Recruiting
Early Phase 1

HSCT

Sponsor:

Children's Hospital of Philadelphia

Code:

NCT02356653

Conditions

Leukemia

Inborn Errors of Metabolism

Bone Marrow Failure Syndromes

Immunodeficiencies

Immunodysregulation Polyendocrinopathy Enteropathy X-linked Syndrome

Eligibility Criteria

Sex: All

Age: 0 - 30

Healthy Volunteers: Not accepted

Interventions

Transplant of stem cells with CD3+/CD19+ depletion (CliniMACs)

Study Details

Brief summary:

The goal of this protocol is to expand access for patients who lack a fully HLA (Human leukocyte antigen) matched sibling donor and who are candidates for allogeneic hematopoietic stem cell transplant (HSCT). These patients have a serious or immediately life-threatening disease for which HSCT is indicated. These patients are not eligible for other Children's Hospital of Philadelphia IRB approved protocols that utilize CliniMACs technology for T depletion.

Conditions

Leukemia

Inborn Errors of Metabolism

Bone Marrow Failure Syndromes

Immunodeficiencies

Immunodysregulation Polyendocrinopathy Enteropathy X-linked Syndrome

Study ID

NCT02356653

Start date

Dec, 2013

Status verified date

Feb, 2026

Completion date

Jan, 2030

Anticipated

Primary completion date

Jan, 2027

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 0 - 30

Healthy Volunteers: Not accepted

Inclusion Criteria:

1. Patients who lack a fully HLA matched sibling and who are candidates for allogeneic hematopoietic stem cell transplant (HSCT) but are not deemed suitable candidates per their treating clinical team for current open institutional protocols using ClinMACs device for CD3+/CD19+ depletion.
2. Patients with the following transplantable diseases:

Non-malignant diseases:

Metabolic storage diseases correctable by HSCT, Bone marrow failure syndromes, Immunodeficiencies/immune dysregulation syndromes/including HLH, Hemoglobinopathies correctable and requiring HSCT, and Other diseases treated with HSCT/Other non-malignant blood, metabolic, or immune disorders for which HSCT has been recommended

Malignant diseases:

Acute leukemias, Chronic leukemias, Lymphomas, Myelodyplastic syndrome
3. Signed informed consent
4. Lansky or Karnofsky performance ≥60
5. Hematologic and Organ Function per current institutional SOP.
6. Infectious Evaluation as per current institutional SOP.
7. Participants of childbearing potential must have a negative pregnancy test as per institutional SOP
8. In cases that are deemed clinical emergencies (primary or secondary graft failure, severe marrow suppression), the above status criteria will be waived.
9. Patients must have an identified living donor

  • Donor selection will comply with 21 CFR 1271
  • Unrelated donor that meets the matching criteria of the NMDP with allele matching at HLA -A, -B, -C, -DRB1, and -DQB1: Unrelated donors may be a 10/10 match, a 9/10 match, or an 8/10 match if one of the mismatches is at DQB1
  • Related donor suitable for mobilization infectious disease criteria as per SOP, including HIV, HepB, HepC PCR negative.
  • CHOP BMT procedures apply for determining donor eligibility, including donor screening and testing for relevant communicable disease agents and diseases. Our donor collection program is FACT accredited.
  • Unrelated donor identified through the National Marrow Donor Program (NMDP) and fulfills the NMDP criteria for donation. Unrelated donor willing and able to undergo mobilization of peripheral stem cells and apheresis.
  • The donors selected for this IND will either be unrelated donors identified through the National Marrow Donor Program (NMDP) or related donors. Regarding the unrelated donors; NMDP procedures for determining donor eligibility include donor screening and testing for relevant communicable disease agents and diseases

Exclusion Criteria:

1. Uncontrolled bacterial, viral or fungal infections
2. Suitable, fully HLA matched sibling donor
3. Donor unable to donate peripheral stem cells
4. Pregnant participants

Study Design

Enrollment

100 participants

Anticipated

Intervention Model

Single group

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

experimental: Expanded access to CliniMACs device for T cell depletion

access for patients who lack a fully HLA matched sibling, and who are candidates for allogeneic hematopoietic stem cell transplant (HSCT). These patients have a serious or immediately life-open protocols that utilize CliniMACs technology for T depletion. Subjects will undergo transplant of stem cells with CD3+/CD19+ depletion.

Interventions

Transplant of stem cells with CD3+/CD19+ depletion (CliniMACs)

Processing of stem cells using the CliniMACs device to selectively deplete specific T cells to decrease risk of graft versus host disease when using donor stem cells which are not fully matched.

Primary outcome measure

  • Overall Survival [ Time Frame: 1 year post transplant ]

Central Contacts and Locations

Central contacts

Patricia Hankins, BSN, RN, CCRC

215-590-5168hankinsp@chop.edu

Locations

Children's Hospital of Philadelphia

Recruiting

Philadelphia, Pennsylvania, United States, 19104

Contacts

Patricia Hankins, BSN, RN, CCRC

215-590-5168hankinsp@chop.edu

Principal Investigator:

Timothy Olson, MD, PhD

More Information

Sponsor

Children's Hospital of Philadelphia

Last update posted

Feb 20, 2026

Last verified

Feb, 2026

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-08. This information was provided to ClinicalTrials.gov by Children's Hospital of Philadelphia on 2026-02-20.